Shruti Bhatt

This study identifies that macrophage-secreted pyrimidine metabolites confer chemotherapy resistance in AML by inhibiting drug activation, and shows that targeting macrophage metabolism can restore drug sensitivity.

This study identifies that TP53 mutations in AML lead to resistance to VenAza therapy by blocking caspase-3/7 activation after mitochondrial outer membrane permeabilization.

This study identifies BIRC5 as a targetable vulnerability in TP53 mutant AML, showing that survivin/IAP inhibitors can overcome therapy resistance.